These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

696 related items for PubMed ID: 15087669

  • 1. Grading ovarian serous carcinoma using a two-tier system.
    Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG.
    Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
    [Abstract] [Full Text] [Related]

  • 2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG, Gershenson DM, Malpica A, Deavers M.
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [Abstract] [Full Text] [Related]

  • 3. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX, Yu L, Bi R, Yang WT.
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
    Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM.
    Cancer; 2012 Jun 15; 118(12):3087-94. PubMed ID: 22072418
    [Abstract] [Full Text] [Related]

  • 6. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.
    Ahmed Q, Hussein Y, Hayek K, Bandyopadhyay S, Semaan A, Abdul-Karim F, Al-Wahab Z, Munkarah AR, Elshaikh MA, Alosh B, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi R.
    Gynecol Oncol; 2014 Feb 15; 132(2):372-6. PubMed ID: 24262874
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
    Seidman JD, Horkayne-Szakaly I, Cosin JA, Ryu HS, Haiba M, Boice CR, Yemelyanova AV.
    Gynecol Oncol; 2006 Nov 15; 103(2):703-8. PubMed ID: 16828848
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.
    Battista MJ, Cotarelo C, Almstedt K, Heimes AS, Makris GM, Weyer V, Schmidt M.
    Arch Gynecol Obstet; 2016 Sep 15; 294(3):599-606. PubMed ID: 26993518
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG.
    Pathology; 2011 Aug 15; 43(5):420-32. PubMed ID: 21716157
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.